Chapter 2: Clinical and Mechanistic Potential of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors in Heart Failure with Preserved Ejection Fraction
Key result
SGLT2 inhibitors reduce heart failure events and CV death in HFpEF via cardio-renal-metabolic pathways.
Why the study?
Disease-modifying therapies for HFpEF have been severely lacking, and the precise mechanisms underpinning the clinical impact of SGLT2 inhibitors remain incompletely resolved.
Do SGLT2 inhibitors improve clinical outcomes in patients with heart failure with preserved ejection fraction?
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support SGLT2 inhibitor consideration in HFpEF; leaves open confirmation in prospective RCTs.
Structured PICO
Do SGLT2 inhibitors improve clinical outcomes in patients with heart failure with preserved ejection fraction?
P
Population
Patients with heart failure with preserved ejection fraction (HFpEF)
I
Intervention
Sodium-glucose co-transporter 2 inhibitors (SGLT2i)
SGLT2 inhibitors offer unique promise in addressing the complex multisystem pathophysiology of HFpEF, reducing heart failure events and cardiovascular death.
Cite This Study
Ostrominski et al. (2023) conducted a review in Heart Failure with Preserved Ejection Fraction (HFpEF). Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors was evaluated. SGLT2 inhibitors significantly reduce heart failure events and cardiovascular death in patients with HFpEF through their impact on numerous cardio-renal-metabolic pathways.